AZ NSCLC
Research type
Research Study
Full title
Real-World Study of Early-Stage (I, II, III) Non–Small Cell Lung Cancer (NSCLC): Prevalence of EGFR Mutations, Treatment and Outcomes
IRAS ID
299949
Contact name
Jason Chow
Contact email
Duration of Study in the UK
0 years, 4 months, 31 days
Research summary
This is a retrospective, noninterventional history study of patients with early stage (I, II, III) non small cell lung cancer. Data collection will be carried out via chart review at participating site in the US, the UK, Canada, Taiwan, South Korea, France, Austria and Germany. Target sample size is 1200 (n=200 in the UK).
Patient charts to be included will be selected according to the protocol-defined eligibility criteria. Data on each patient will be collected starting at initial diagnosis of NSCLC until the end of available follow-up (i.e., date of mortality, date of last visit, treatment administration or hospitalization, or loss to follow-up). All patients included must have been diagnosed between January 4, 2014 and December 31, 2017. The maximum date of follow-up (retrospectively observed) will be December 31, 2020, allowing up to 7 years of follow-up after the initial NSCLC diagnosis.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
21/SC/0264
Date of REC Opinion
2 Aug 2021
REC opinion
Favourable Opinion